33 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00028 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 14.2% inhibition at 10-6 M |
| dbacp00029 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 19.7% inhibition at 10-5 M |
| dbacp00030 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 24.9% inhibition at 10-4 M |
| dbacp00031 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 30.4% inhibition at 10-3 M |
| dbacp00053 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.2% inhibition at 10-6 M |
| dbacp00054 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.4% inhibition at 10-5 M |
| dbacp00055 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.2% inhibition at 10-4 M |
| dbacp00056 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 21.2% inhibition at 10-3 M |
| dbacp00078 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.5% inhibition at 10-6 M |
| dbacp00079 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.9% inhibition at 10-5 M |
| dbacp00080 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 1.9% inhibition at 10-4 M |
| dbacp00081 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 16.2% inhibition at 10-3 M |
| dbacp00125 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.7% inhibition at 10-6 M |
| dbacp00126 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.0% inhibition at 10-5 M |
| dbacp00127 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 18.8% inhibition at 10-4 M |
| dbacp00128 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 26.7% inhibition at 10-3 M |
| dbacp00159 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.6% inhibition at 10-6 M |
| dbacp00160 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.9% inhibition at 10-5 M |
| dbacp00161 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 12.6% inhibition at 10-4 M |
| dbacp00162 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 26.4% inhibition at 10-3 M |
| dbacp00192 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 1.0% inhibition at 10-6 M |
| dbacp00193 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 10.1% inhibition at 10-5 M |
| dbacp00194 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 16.8% inhibition at 10-4 M |
| dbacp00195 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 36.1% inhibition at 10-3 M |
| dbacp00226 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 13.7% inhibition at 10-6 M |
| dbacp00227 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 25.8% inhibition at 10-5 M |
| dbacp00228 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 34.7% inhibition at 10-4 M |
| dbacp00229 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 44.5% inhibition at 10-3 M |
| dbacp00279 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 3.9% inhibition at 10-5 M |
| dbacp00280 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 45% inhibition at 10-3 M |
| dbacp06940 | PS14 | PTECQVGTTCKVES | Aphanomyces invadans | Not available | LDH leakage assay | Hep-2 | Larynx Cancer | 45.56 ± 2% LDH release at 20 µM |
| dbacp06941 | PS14 | PTECQVGTTCKVES | Aphanomyces invadans | Apoptosis inducing | MTT assay | Hep-2 | Larynx Cancer | IC50 = 21 µM |
| dbacp08302 | RF13 | RRGKGGRRVTMSF | VSP26B of C. striatus | Not Available | MTT assay | HEp-2 | Larynx Cancer | IC50 = 49.65 µM |